Shilpa Therapeutics Pvt. Ltd. scheme of amalgamation approved by NCLT Bengaluru
Shilpa Medicare · Pharmaceuticals & Biotechnology
Key highlights
- Amalgamation of wholly owned subsidiary (Transferor Company) with holding company (Transferee Company) approved, appointed date changed to 01.04.2025
- Petitioner companies must register certified copy of order with Registrar of Companies Karnataka within 30 days and comply with Income Tax Act provisions
- Transferee Company to settle MSME dues, preserve Transferor Company records, and comply with all applicable laws including stamp duty, SEBI, and related party transaction provisions
Why it's rated notable: A court-approved merger of a wholly owned subsidiary into the listed company with no shares issued and no value stated is an internal restructuring, so it is medium at most.
Original filing
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Shilpa Medicare
- Financial resultsMajor developmentShilpa Medicare Q1 results approved; consolidated net profit Rs. 10,088 lakhs
- Capex / expansionNotableShilpa Medicare commissions state-of-the-art ADC GMP manufacturing facility
Other order win filings this fortnight
- HLE Glascoat subsidiary Kinam Engineering secures $42-48M international order
- SpectraA Technology Solutions receives ₹21 crore domestic order for brewery project
- Ashoka Buildcon receives LoA for NHAI expressway project worth ₹865.90 crore
- L&T bags significant order from Noida Metro for Aqua Line Extension
- South West Pinnacle Exploration H1 FY27 revenue up 16% to Rs. 1194 Mn, PAT up 23%
- SEAMEC Limited awarded USD 26.14 million subsea installation contract by L&T
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.